By Lewis Krauskopf
NEW YORK (Reuters) – Sluggish U.S. biotech shares could require a wave of deal-making or exciting clinical trial results if the sector wants to join the stock market’s party after lagging Wall Street’s broad advance this year.
More certainty…
Analysis-Deals, data buzz could help biotech shares exit Wall St’s ‘no man’s land’
Share this article
More News
Oracle Corp Stock (ORCL) Closed Down by 3.07% on Sep 15: A Full Analysis
September 16, 2026
Crypto.com and Robinhood ask Supreme Court on markets
September 16, 2026
Figma Stock Analysis: Buy or Sell?
September 16, 2026
The crypto Clarity Act voted down in Senate
September 16, 2026
Chip Stocks Sink on AI Slowdown Calls, But Analysts Doubt a Crash Is Near
September 16, 2026
Bitcoin Falls Below $75,000, Crypto Stocks Plunge as Clarity Act Vote Fails
September 16, 2026